A Mechanism Exploration for the Yi-Fei-San-Jie Formula against Non-Small-Cell Lung Cancer Based on UPLC-MS/MS, Network Pharmacology, and <i>In Silico</i> Verification.

Publication Year: 2023

DOI:
10.1155/2023/3436814

PMCID:
PMC9842415

PMID:
36654811

Journal Information

Full Title: Evid Based Complement Alternat Med

Abbreviation: Evid Based Complement Alternat Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Integrative & Complementary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"data availability all the results used to support this work are included in the article. more details were deposited in the science data bank (doi"

Code Sharing
Evidence found in paper:

"Conflicts of Interest The authors declare that there are no conflicts of interest."

Evidence found in paper:

"This work was supported by the Collaborative Innovation Research and High-Level Team Building of Integrated Chinese and Western Medicine in Diagnosis and Treatment of Malignant Tumors (No. 2021XK09), the Basic Theoretical Research of Chinese Medicine of the Guangzhou University of Chinese Medicine (Jiebang Guashuai Lizhu Lin project, No. Project [2022]-7), the Cooperative Research of High-Level Hospital Project (Lung Cancer) (2019–2022), the National Natural Science Foundation of China (No. 82104647 and No. 81973775), and the Postdoctoral Science Foundation of China (No. 2021M700964). The authors thank Bullet Edits Limited for the linguistic editing and proofreading of the manuscript."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025